TY - JOUR
T1 - Identification of b.1.346 lineage of sars-cov-2 in japan
T2 - Genomic evidence of re-entry of clade 20c
AU - Abe, Kodai
AU - Shimura, Takako
AU - Takenouchi, Toshiki
AU - Iwasaki, Yuka W.
AU - Ishizu, Hirotsugu
AU - Uwamino, Yoshifumi
AU - Uno, Shunsuke
AU - Gotoh, Jun
AU - Tachikawa, Natsuo
AU - Takeuchi, Yuriko
AU - Katayama, Junpei
AU - Nozaki, Hiroyuki
AU - Fujii, Susumu
AU - Seki, Shikou
AU - Nakamura, Morio
AU - Uda, Kazuhiro
AU - Misumi, Takahiko
AU - Ishihara, Jun
AU - Yamada, Kenichiro
AU - Kanai, Toshio
AU - Murai, Shinji
AU - Araki, Kazuhiro
AU - Ebihara, Tamotsu
AU - Siomi, Haruhiko
AU - Hasegawa, Naoki
AU - Kitagawa, Yuko
AU - Amagai, Masayuki
AU - Suematsu, Makoto
AU - Kosaki, Kenjiro
N1 - Funding Information:
We thank all the patients and healthcare workers who have fought against COVID-19. This work was supported by the Keio Donner Project and is devoted to the late Professor Shibasaburo Kitasato, the founder of Keio University School of Medicine. We also thank SRL, Inc. Funding provided by Keio Gijuku Academic Development Funds and the Japan Agency for Medical Research Development (AMED JP20he0622043, K.K. as the Lead) was used to acquire consumables and to carry out deep sequencing of viral genomes. The cost of consumables was also supported in part by Ryoshoku-Kenkyu-kai, which aims to tackle infections disease control (M.S.). The design and data analyses of this study were performed independently of the funding agencies.
Funding Information:
We thank all the patients and healthcare workers who have fought against COVID-19. This work was supported by the Keio Donner Project and is devoted to the late Pro-fessor Shibasaburo Kitasato, the founder of Keio University School of Medicine. We also thank SRL, Inc. Funding provided by Keio Gijuku Academic Development Funds and the Japan Agency for Medical Research Development (AMED JP20he0622043, K.K. as the Lead) was used to acquire consumables and to carry out deep sequencing of viral genomes. The cost of consumables was also supported in part by Ryoshoku-Kenkyu-kai, which aims to tackle infections disease control (M.S.). The design and data analyses of this study were performed independently of the funding agencies.
Publisher Copyright:
© 2021 by The Keio Journal of Medicine.
PY - 2021
Y1 - 2021
N2 - SARS-CoV-2 whole-genome sequencing of samples from COVID-19 patients is useful for informing infection control. Datasets of these genomes assembled from multiple hospitals can give critical clues to regional or national trends in infection. Herein, we report a lineage summary based on data collected from hospitals located in the Tokyo metropolitan area. We performed SARS-CoV-2 whole-genome sequencing of specimens from 198 patients with COVID-19 at 13 collaborating hospitals located in the Kanto region. Phylogenetic analysis and fingerprinting of the nucleotide substitutions were performed to differentiate and classify the viral lineages. More than 90% of the identified strains belonged to Clade 20B, which has been prevalent in European countries since March 2020. Only two lineages (B.1.1.284 and B.1.1.214) were found to be predominant in Japan. However, one sample from a COVID-19 patient admitted to a hospital in the Kanto region in November 2020 belonged to the B.1.346 lineage of Clade 20C, which has been prevalent in the western United States since November 2020. The patient had no history of overseas travel or any known contact with anyone who had travelled abroad. Consequently, the Clade 20C strain belonging to the B.1.346 lineage appeared likely to have been imported from the western United States to Japan across the strict quarantine barrier. B.1.1.284 and B.1.1.214 lineages were found to be predominant in the Kanto region, but a single case of the B.1.346 lineage of clade 20C, probably imported from the western United States, was also identified. These results illustrate that a de-centralized network of hospitals offers significant advantages as a highly responsive system for monitor-ing regional molecular epidemiologic trends.
AB - SARS-CoV-2 whole-genome sequencing of samples from COVID-19 patients is useful for informing infection control. Datasets of these genomes assembled from multiple hospitals can give critical clues to regional or national trends in infection. Herein, we report a lineage summary based on data collected from hospitals located in the Tokyo metropolitan area. We performed SARS-CoV-2 whole-genome sequencing of specimens from 198 patients with COVID-19 at 13 collaborating hospitals located in the Kanto region. Phylogenetic analysis and fingerprinting of the nucleotide substitutions were performed to differentiate and classify the viral lineages. More than 90% of the identified strains belonged to Clade 20B, which has been prevalent in European countries since March 2020. Only two lineages (B.1.1.284 and B.1.1.214) were found to be predominant in Japan. However, one sample from a COVID-19 patient admitted to a hospital in the Kanto region in November 2020 belonged to the B.1.346 lineage of Clade 20C, which has been prevalent in the western United States since November 2020. The patient had no history of overseas travel or any known contact with anyone who had travelled abroad. Consequently, the Clade 20C strain belonging to the B.1.346 lineage appeared likely to have been imported from the western United States to Japan across the strict quarantine barrier. B.1.1.284 and B.1.1.214 lineages were found to be predominant in the Kanto region, but a single case of the B.1.346 lineage of clade 20C, probably imported from the western United States, was also identified. These results illustrate that a de-centralized network of hospitals offers significant advantages as a highly responsive system for monitor-ing regional molecular epidemiologic trends.
KW - COVID-19
KW - Mutation
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85109012893&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109012893&partnerID=8YFLogxK
U2 - 10.2302/kjm.2021-0005-OA
DO - 10.2302/kjm.2021-0005-OA
M3 - Article
C2 - 33853975
AN - SCOPUS:85109012893
SN - 0022-9717
VL - 70
SP - 44
EP - 50
JO - Keio Journal of Medicine
JF - Keio Journal of Medicine
IS - 2
ER -